Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Trastuzumab 25Carboplatin 20Paclitaxel 19pertuzumab 18pyrotinib 17Cyclophosphamide 17Capecitabine 16Docetaxel 15trastuzumab deruxtecan 14Radiotherapy 13Drug Therapy 13Standard of Care 12Letrozole 12Fulvestrant 12dalpiciclib 11pembrolizumab 9exemestane 9Epirubicin 9Anastrozole 9sacituzumab govitecan 8palbociclib 8eribulin 8Specimen Handling 8Doxorubicin 7130-nm albumin-bound paclitaxel 7toripalimab 6abemaciclib 6Tamoxifen 6Neoadjuvant Therapy 6Magnetic Resonance Spectroscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × ivarmacitinib × Breast × Clear all
NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Fudan University

Phase 2 Not yet recruiting
40 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡